188577-70-0Relevant articles and documents
Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-RafV600E inhibitors
Li, Xiaokai,Shen, Jiayi,Tan, Li,Zhang, Zhang,Gao, Donglin,Luo, Jinfeng,Cheng, Huimin,Zhou, Xiaoping,Ma, Jie,Ding, Ke,Lu, Xiaoyun
, p. 2760 - 2763 (2016)
B-RafV600E was an effective target for the treatment of human cancers. Based on a pan-Raf inhibitor TAK-632, a series of N-(4-aminopyridin-2-yl)amide derivatives were designed as novel B-RafV600E inhibitors. Detailed structure-activi
HETEROCYCLIC COMPOUNDS AND METHODS OF USE
-
Paragraph 000294, (2020/02/06)
The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
-
Paragraph 0554-0555, (2017/01/02)
The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a